Drugs & Targets FDA grants Fast Track designation for ¹⁷⁷Lu-PNT2002 for metastatic castration-resistant prostate cancer April 28, 2023Vol.49 No.17
Guest Editorial Mifepristone and the Administrative Procedure Act: Perspective of a former FDA commissioner and NCI director April 14, 2023Vol.49 No.15By Norman E. "Ned" Sharpless
Pragmatica-Lung, a landmark pragmatic trial with registrational intent, starts enrollment April 14, 2023Vol.49 No.15By Jacquelyn Cobb
Conversation with The Cancer LetterRegulatory News FDA’s Fashoyin-Aje: Draft guidance on accelerated approval urges reliance on randomized controlled trials March 31, 2023Vol.49 No.13By Jacquelyn Cobb
Drugs & Targets FDA grants full approval indication for Keytruda for certain patients with advanced MSI-H or dMMR solid tumors March 31, 2023Vol.49 No.13
Drugs & Targets FDA releases draft guidance aimed at improving oncology clinical trials for accelerated approval March 24, 2023Vol.49 No.12
Drugs & Targets FDA grants accelerated approval to Zynyz for metastatic or recurrent locally advanced Merkel cell carcinoma March 24, 2023Vol.49 No.12
Drugs & Targets FDA approves Tafinlar + Mekinist for pediatric patients with low-grade glioma with a BRAF V600E mutation March 17, 2023Vol.49 No.11
Regulatory News Improving on R-CHOP, ODAC votes 11:2 to move Genentech’s Polivy to the first line in diffuse large B-cell lymphoma March 10, 2023Vol.49 No.10By Jacquelyn Cobb
Drugs & Targets FDA broadens indication for Verzenio in HR+, HER2-, node-positive, high-risk early breast cancer March 10, 2023Vol.49 No.10
